Enric Carcereny

5PUBLICATIONS
96CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 17, 2026
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Ben Tran, Mark Voskoboynik, Sang-We Kim

|Sep 09, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.

Ross A Soo, Urania Dafni, Ji-Youn Han

|Jul 12, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.

Martin Forster, Irene Brana, Antonio L Pousa

|Jun 11, 2024
Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.

Enric Carcereny, Delvys Rodriguez-Abreu, Rafael Lopez

|Apr 17, 2024
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.

Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti

Pageof 1

Frequent Collaborators

3 joint publications

Mariano Provencio Pulla

2 joint publications

Javier de Castro

1 joint publications

Melina Peressini

1 joint publications

Rosario Garcia-Campelo